Ronald Witteles
@Ron_Witteles
Stanford IM residency program director, Professor of Medicine, Cardiologist, Specialist in Amyloidosis, Sarcoidosis, Cardio-Oncology, and Advanced heart failure
22-10-2016 17:57:46
1,9K Tweets
4,5K Followers
285 Following
(1/10) Today the long-awaited full results from the Phase 3 ATTRibute-CM trial were presented European Society of Cardiology #ESCCongress . We already knew the topline results from last month: Acoramidis made a (big) difference in outcomes! What more did we learn?🤔Let's dig deeper...
